Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs

Table 4

List of nontype 1 ROP cases that received intravitreal injection of anti-VEGF drugs (N  = 39).

ID.	Gender	GA (w)	BW (kg)	Eyes	Zone^а	Stage	Plus^β	Range (hr)	Time of the first treatment (week)	Medicine^β	Reasons for treatment^γ
1	Male	26.6	0.95	OD	II	2	±	7	42.2	C	Preplus
				OS	II	2	±	7	42.2	C	Preplus
2	Male	27.6	1.00	OD	II	2	±	6	43.6	C	Follow-up time ≥44 w, ridge aggravation, preplus
				OS	II	2	±	6	43.6	C	Follow-up time ≥44 w, preplus
3	Male	30.0	1.30	OD	II	3	±	6	41.3	C	Ridge aggravation, preplus
				OS	II	2	−	6	42.3	C	Ridge aggravation, contralateral eye
4	Female	29.0	0.90	OD	II	2	−	5	45.7	C	Follow-up time ≥44 w, logistical considerations
				OS	II	2	-	5	46.7	C	Follow-up time ≥44 w, logistical considerations
5	Male	28.7	1.30	OD	I	1	±	12	34.0	C	Preplus, logistical considerations
				OS	I	1	±	12	34.0	C	Preplus, logistical considerations
6	Female	30.0	1.66	OD	II	2	±	5	38.0	R	Preplus
				OS	II	3	±	5	39.0	R	Preplus
7	Female	27.6	1.10	OD	II	3	±	12	38.6	R	Ridge aggravation, preplus
				OS	II	3	±	12	38.6	R	Ridge aggravation, preplus
8	Female	27.0	0.98	OD	II	2	±	5	36.3	C	Preplus
				OS	II	2	±	5	37.3	C	Preplus
9	Male	29.4	1.10	OD	II	2	±	6	40.7	R	Preplus
				OS	II	2	±	6	40.7	R	Preplus
10	Male	32.0	1.50	OD	II	3	−	6	40.9	R	Type 1
				OS	II	3	±	6	40.9	R	Ridge aggravation, preplus, contralateral eye
11	Male	30.7	1.66	OD	II	2	±	5	35.6	C	Preplus
				OS	II	2	±	7	35.6	C	Preplus
12	Male	30.0	1.63	OD	II	3	−	5	38.4	A	Type 1
				OS	II	3	±	5	38.4	A	Ridge aggravation, preplus, contralateral eye
13	Male	26.9	0.72	OD	II	3	±	12	37.6	C	Preplus
				OS	II	2	−	12	NA	NA	Untreated
14	Female	28.4	1.05	OD	II	3	−	5	44.7	C	Follow-up time ≥44 w, ridge aggravation
				OS	II	3	−	5	44.7	C	Follow-up time ≥44 w, ridge aggravation
15	Female	28.9	1.13	OD	Posterior II	2	−	12	39.8	C	Contralateral eye
				OS	Posterior II	2	+	12	39.8	C	Type 1
16	Female	27.0	0.73	OD	III	2	−	3	NA	NA	Untreated
				OS	II	3	±	4	39.7	C	Ridge aggravation, preplus
17	Female	26.7	0.71	OD	II	2	±	6	39.8	C	Preplus
				OS	II	2	±	6	39.8	C	Preplus
18	Male	27.3	1.10	OD	II	2	±	10	37.7	C	Preplus
				OS	II	2	±	10	37.7	C	Preplus
19	Female	25.6	0.90	OD	II	2	−	3	NA	NA	Untreated
				OS	II	3	±	3	39.6	C	Ridge aggravation, preplus
20	Male	26.7	0.85	OD	II	3	±	7	43.3	C	Ridge aggravation, preplus
				OS	II	2	−	6	NA	NA	Untreated
21	Female	25.9	0.86	OD	Posterior II	2	±	10	38.0	C	Preplus
				OS	Posterior II	2	±	10	38.0	C	Preplus
22	Male	26.9	0.68	OD	II	2	±	12	37.2	A	Preplus
				OS	II	2	±	12	37.2	A	Preplus
23	Male	27.6	1.10	OD	Posterior II	3	±	12	36.6	A	Preplus
				OS	Posterior II	3	±	12	36.6	A	Preplus
24	Male	28.0	1.17	OD	II	2	±	10	37.1	C	Preplus
				OS	II	2	±	10	37.1	C	Preplus
25	Male	31.0	1.75	OD	II	3	±	5	38.9	A	Ridge aggravation, preplus
				OS	II	2	−	5	38.9	A	Contralateral eye
26	Female	27.9	1.13	OD	II	2	±	5	40.5	C	Preplus
				OS	II	2	±	5	40.5	C	Preplus
27	Female	29.4	1.00	OD	II	2	±	6	43.4	C	Preplus
				OS	II	2	−	5	NA	NA	Untreated
28	Female	27.0	1.10	OD	II	3	±	5	42.6	C	Ridge aggravation, preplus
				OS	II	3	±	5	42.6	C	Ridge aggravation, preplus
29	Female	27.3	1.08	OD	II	2	±	5	37.7	C	Preplus
				OS	II	2	±	5	37.7	C	Preplus
30	Male	28.4	1.19	OD	II	2	−	4	NA	NA	Untreated
				OS	II	3	±	4	43.8	C	Preplus
31	Male	26.7	0.75	OD	II	2	±	10	40.8	C	Preplus
				OS	II	2	±	10	40.8	C	Preplus
32	Female	29.7	1.25	OD	II	3	±	6	40.0	C	Ridge aggravation, preplus
				OS	II	3	±	6	40.0	C	Ridge aggravation, preplus
33	Female	33.1	1.80	OD	II	2	±	5	44.8	C	Ridge aggravation, preplus, follow-up time ≥44 w
				OS	II	3	±	6	44.8	C	Ridge aggravation, preplus, follow-up time ≥44 w
34	Male	27.9	0.97	OD	II	2	+	12	36.9	R	Type 1
				OS	II	2	±	12	36.9	R	Preplus, contralateral eye
35	Female	27.9	1.18	OD	II	2	−	3	NA	NA	Untreated
				OS	II	3	±	3	39.8	C	Ridge aggravation, preplus
36	Male	31.9	2.28	OD	II	2	±	6	39.0	A	Contralateral eye, preplus
				OS	II	3	±	6	39.0	A	Ridge aggravation, preplus
37	Male	25.6	0.74	OD	II	2	±	12	39.0	C	Preplus
				OS	II	2	±	12	39.0	C	Preplus
38	Male	30.6	1.50	OD	II	2	±	6	37.7	A	Preplus, contralateral eye
				OS	II	2	+	6	37.7	A	Type 1
39	Female	29.0	1.26	OD	II	3	+	5	40.9	C	Type 1
				OS	II	2	±	6	40.9	C	Ridge aggravation, preplus, contralateral eye

^αII referred to periphery zone II. ^β ± referred to preplus. ^γ R, C, and A represent ranibizumab, conbercept, and aflibercept. NA refers untreated. ^δOne eye of type 1 ROP and the contralateral eye of nontype 1 ROP in 6 cases (ID. 10, 12, 15, 34, 38, 39). One eye of nontype 1 ROP and contralateral eye untreated in 7 cases (ID. 13, 16, 19, 20, 27, 30, 35).